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Hyper-IgM (HIGM) syndromes are primary 
immunodefi  ciencies characterized by defects 
in class switch recombination (CSR), resulting 
in severely decreased numbers of circulating 
isotype-switched memory B cells. As a conse-
quence, HIGM patients who display normal 
to elevated serum IgM levels combined with 
severely decreased serum levels of IgG, IgA, and 
IgE suff  er from recurrent bacterial infections 
(1–3). The genetic basis of HIGM is diverse 
and is caused either by defects in the CD40L–
CD40 pathway, which is essential for B cell 
activation, germinal center (GC) formation, and 
CSR induction, or by defects involving the 
enzymes required for CSR (3). An X-linked 
form of the disease results from mutations in 
the CD40L (or CD154) gene; it is the most 
prevalent form of HIGM, accounting for a 
majority of the cases (4, 5). CD40L-defi  cient 
patients lack GCs and fail to develop normal 
antibody responses (4, 6). A B-cell intrinsic 
defect caused by rare mutations in the CD40L 
receptor CD40 results in an autosomal form of 
the disease, which is clinically indistinguishable 
from HIGM caused by defective CD40L (7). 
Abnormal CD40 signaling in the absence of 
functional nuclear factor-κB essential modula-
tor (NEMO or IKKγ) also induces a form of 
HIGM that is associated with anhydrotic ecto-
dermal dysplasia, which is a key feature of this 
syndrome (8, 9).
Mutations in genes encoding enzymes re-
quired for CSR and somatic hypermutations 
(SHMs) also result in HIGM. Activation-
i  nduced cytidine deaminase (AID) is induced in 
GC B cells, and defects in AID gene expression 
and/or function cause an autosomal recessive 
form of HIGM that is characterized by the pres-
ence of enlarged GCs and the absence of CSR 
and SHMs in both mice and humans (10–12). 
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Hyper-IgM (HIGM) syndromes are primary immunodefi  ciencies characterized by defects of 
class switch recombination and somatic hypermutation. HIGM patients who carry mutations 
in the CD40-ligand (CD40L) gene expressed by CD4+ T cells suffer from recurrent infec-
tions and often develop autoimmune disorders. To investigate the impact of CD40L–CD40 
interactions on human B cell tolerance, we tested by ELISA the reactivity of recombinant 
antibodies isolated from single B cells from three CD40L-defi  cient patients. Antibody 
characteristics and reactivity from CD40L-defi  cient new emigrant B cells were similar to 
those from healthy donors, suggesting that CD40L–CD40 interactions do not regulate 
central B cell tolerance. In contrast, mature naive B cells from CD40L-defi  cient patients 
expressed a high proportion of autoreactive antibodies, including antinuclear antibodies. 
Thus, CD40L–CD40 interactions are essential for peripheral B cell tolerance. In addition, 
a patient with the bare lymphocyte syndrome who could not express MHC class II molecules 
failed to counterselect autoreactive mature naive B cells, suggesting that peripheral B cell 
tolerance also depends on major histocompatibility complex (MHC) class II–T cell receptor 
(TCR) interactions. The decreased frequency of MHC class II–restricted CD4+ regulatory 
T cells in CD40L-defi  cient patients suggests that these T cells may mediate peripheral B cell 
tolerance through CD40L–CD40 and MHC class II–TCR interactions.
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Another CSR defi  ciency has been correlated to mutations in 
the uracil-DNA glycosylase (UNG) gene that encodes a DNA 
repair enzyme that acts downstream of AID (13). In addi-
tion, 20–30% of HIGM patients have no identifi  ed mutations 
in CD40L, CD40, NEMO, AID, and UNG, suggesting that 
mutations in other unknown genes result in additional forms 
of HIGM (5, 14).
Impaired immune functions leading to primary immuno-
defi  ciencies often correlate with paradoxical autoimmune 
complications. Aside from the susceptibility to opportunistic 
and bacterial infections, CD40L-defi  cient patients are also 
prone to develop autoimmune diseases such as thrombocyto-
penia, hemolytic anemia, and nephritis, suggesting that B cell 
tolerance is not properly established and/or maintained in 
these patients (1–3, 15). In line with this hypothesis, it has 
been reported that sera from CD40L-defi  cient patients con-
tain natural antibodies biased toward specifi  c self-antigens that 
were not found in the sera of healthy donors (HDs), thereby 
suggesting an abnormal B cell selection in these patients (16). 
Although the molecular mechanisms by which CD40L induces 
B cell proliferation and diff  erentiation are well described, 
its potential functions in counterselecting human autoreactive 
B cells are poorly characterized. Transgenic mouse models have 
suggested that CD4+ T cells may play an important role in the 
elimination of peripheral autoreactive B cells (17). In addi-
tion, CD40L–CD40 and MHC class II–T cell receptor inter-
actions were required for the counterselection of transgenic 
autoreactive B cells (18).
In humans, most developing autoreactive B cells are 
removed at two discrete checkpoints during early B cell devel-
opment (19). A central B cell tolerance checkpoint silences 
polyreactive and ANA-expressing B cells between the early 
immature and immature B cell stages in bone marrow, and 
a peripheral B cell tolerance checkpoint further counter-
se  lects self-reactive clones at the transition between new 
emigrant and mature naive B cells in the periphery (19). 
The regulation of central B cell tolerance involves B cell re-
ceptor (BCR) signaling pathways that regulate recombination 
activating gene expression and central tolerance mechanisms 
such as receptor editing, anergy, and deletion in immature 
B cells (20). Indeed, we previously reported that alterations 
in BCR signaling in X-linked agammaglobulinemia (XLA) 
patients result in a defective central B cell tolerance check-
point, which is illustrated by a failure to counterselect poly-
reactive developing B cells in those patients (21). Little is 
known about the molecules and pathways that regulate 
  human peripheral B cell tolerance checkpoints. To determine 
the impact of CD40L and MHC class II expression on human 
B cell tolerance checkpoints, we cloned and expressed in 
vitro recombinant antibodies from single B cells from three 
CD40L-defi  cient patients and a MHC class II–defi  cient (bare 
lymphocyte syndrome [BLS]) patient, and compared their 
reactivity to that of recombinant antibodies isolated from 
HDs. We report that defects in CD40L and MHC class II 
expression result in the accumulation of autoreactive clones 
in the mature naive B cell compartment of CD40L-defi  cient 
and BLS patients. Thus, CD40L–CD40 and MHC class II 
play an important role in regulating a peripheral B cell 
tolerance checkpoint in humans. The decreased numbers of 
regulatory T (T reg) cells and elevated serum BAFF levels in 
CD40L-defi  cient and BLS patients suggest that T reg cells 
and BAFF are also involved in the regulation of peripheral 
human B cell tolerance.
RESULTS
Central B cell tolerance is functional in patients 
with CD40L mutations
A central B cell tolerance checkpoint normally removes most 
developing B cells that express highly polyreactive antibodies 
in the bone marrow, and only a small fraction of clones with 
low levels of polyreactivity migrate to the periphery (19). 
A peripheral B cell tolerance checkpoint further counterse-
lects autoreactive new emigrant B cells before they enter the 
mature naive B cell compartment (19). Constitutive expres-
sion of CD40 is detected on human B cell precursors in the 
bone marrow and is retained at the mature naive B cell stage, 
but a role for CD40L–CD40 interactions on human B cell 
selection is unknown. To determine if human B cell tolerance 
checkpoints are aff  ected by the absence of CD40L expression, 
we tested the reactivity of antibodies from 98 single periph-
eral CD19+CD10+IgM+CD27− new emigrant B cells and 92 
CD19+CD10−IgM+CD27− mature naive B cells from three 
CD40L-defi  cient patients and compared it to that of anti-
bodies from a teenage HD (HD08) and previously reported 
adult healthy controls (Fig. 1) (19, 21, 22). We found that 
polyreactive B cells represented 4.3, 6.7, and 9.5% of new 
emigrant B cells from the three CD40L-defi  cient patients, 
respectively, and was similar to that of new emigrant B cells 
from HD08 (5.3%) and previously reported adult controls, 
suggesting that there were no defects in central B cell toler-
ance in these patients (Fig. 1, A and B). Mature naive B cells 
from HD08 also contained a low proportion (6.7%) of poly-
reactive clones, similar to their new emigrant B cell counter-
part (Fig. 1 A). In contrast, CD40L-defi  cient mature naive 
B cells displayed a higher frequency of polyreactive antibodies, 
with 13, 13, and 26.1% in patients 1, 2, and 3, respectively 
(Fig. 1 A). When the frequency of polyreactive clones from 
CD40L-defi  cient patients was compared with that of the fi  ve 
HDs of various ages analyzed so far, we found that it was 
increased in the mature naive B cell compartment, and that 
diff  erences reached statistical signifi  cance (P = 0.0262; Fig. 1 B). 
In addition, all CD40L-defi  cient patients showed a higher 
proportion of polyreactive B cells in their mature naive B cells 
than in their new emigrant B cell counterpart from which 
they arose (Fig. 1 C).
Hence, polyreactive B cells are properly counterselected 
in the bone marrow of CD40L-defi  cient patients, revealing a 
functional central B cell tolerance checkpoint in the absence 
of CD40L expression. On the other hand, the peripheral 
B cell tolerance checkpoint seems to be defective in CD40L-
defi  cient patients, resulting in an increase of circulating poly-
reactive B cells.JEM VOL. 204, July 9, 2007  1585
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Figure 1.  CD40L-defi  cient mature naive B cells express polyreactive 
antibodies. (A, top) Antibodies from new emigrant (left) and mature 
naive (right) B cells from a 14-yr-old HD (HD08) and three CD40L-
defi  cient patients were tested in ELISA for reactivity with ssDNA, dsDNA, 
insulin, and LPS. Dashed lines show ED38-positive control (19, 54). 
Horizontal lines show cut-off OD405 for positive reactivity. (bottom) For 
each individual, the frequency of polyreactive (fi  lled area) and nonpoly-
reactive (open area) clones is summarized in pie charts, with the number of 
antibodies tested indicated in the centers. (B) The frequency of polyreactive 
clones in the mature naive fraction of CD40L-defi  cient patients is higher 
than in healthy controls. The proportions of polyreactive B cells in new 
emigrant (left) and mature naive (right) B cells from fi  ve controls and 
three CD40L-defi  cient patients and (C) their evolution between these 
two B cell compartments are represented. Each diamond represents 
an individual, and the mean is shown with a bar. The controls shown 
include the two newly studied HD controls, HD08 and HD09, added to 
the previously reported controls (19, 21, 22). Statistically signifi  cant 
  differences are indicated.1586  DEFECT OF PERIPHERAL B CELL TOLERANCE IN CD40L DEFICIENCY | Hervé et al.
Peripheral mature naive B cells from CD40L-defi  cient 
patients express high levels of autoreactive antibodies
We further assessed the requirement of CD40L for central and 
peripheral B cell tolerance checkpoints by testing by ELISA 
the reactivity of recombinant antibodies from CD40L-defi  cient 
patients against HEp-2 cell lysates. We found that CD40L-
defi   cient patients showed a frequency of HEp-2–reactive 
clones in new emigrant B cells that ranged from 36.2 to 47.6% 
and was similar to that of the teenage HD08 (31.6%) and 
of the previously reported healthy controls (29.2–46.2%; 
Fig. 2, A and B) (19, 21). Similar to adult healthy controls, 
the proportion of HEp-2–reactive antibodies decreased to 
23.3% in the mature naive B cells from HD08 (Fig. 2) 
(19, 21, 22). In contrast, the frequency of mature naive B cells 
that expressed HEp-2–reactive antibodies was signifi  cantly in-
creased in all three CD40L-defi  cient patients compared with 
controls (P = 0.0001; Fig. 2, B and C). Correlating with this 
increase in HEp-2–reactive mature naive B cells in CD40L-
defi  cient patients, we found that these cells expressed heavy 
chain complementarity determining region (CDR) 3s with an 
increased frequency of positively charged residues, which fa-
vor autoreactivity (Fig. S1 and Tables S1–S12, available at 
http://www.jem.org/cgi/content/full/jem.20062287/DC1). 
Thus, the increase in HEp-2–reactive mature naive B cells in 
CD40L-defi  cient patients further demonstrates a defective 
peripheral B cell tolerance checkpoint when CD40L expres-
sion is defi  cient.
CD40L expression is essential to the counterselection 
of ANA B cells
Central B cell tolerance is responsible for the removal of most 
developing B cells expressing ANAs in HDs (19). In CD40L-
defi  cient patients, the central B cell tolerance checkpoint ap-
pears to be normal, but a majority of peripheral mature naive 
B cells express HEp-2–reactive antibodies that may recognize 
nuclear antigens. To determine if HEp-2–reactive B cells from 
HIGM patients express ANAs, we performed indirect immuno-
fl  uorescence assays on fi  xed HEp-2 cells (Fig. 3). We found 
that antibodies from a very small and similar proportion of new 
emigrant B cells from controls and CD40L-defi  cient patients 
expressed ANAs, further demonstrating that central B cell 
tolerance checkpoint was functional in the absence of CD40L 
expression (Fig. 3, A and B). The frequency of nuclear-reactive 
B cells remained very low in the mature naive B cell compart-
ment of healthy controls (Fig. 3, A and B). In contrast, anti-
bodies from CD40L-defi  cient   mature naive B cells showed 
Figure 2.  CD40L-defi  cient mature naive B cells express HEp-2–
reactive antibodies. (A, top) Antibodies from new emigrant (left) and 
mature naive (right) B cells from a young HD, HD08, and three CD40L-
defi  cient patients were tested in ELISA for anti–HEp-2 cell reactivity. 
Dashed lines show ED38-positive control (19, 54). Horizontal lines show 
cut-off OD405 for positive reactivity. (bottom) For each individual, the 
  frequency of HEp-2–reactive (fi  lled area) and non–HEp-2-reactive (open 
area) clones is summarized in pie charts, with the number of antibodies 
tested indicated in the centers. (B) The frequency of HEp-2–reactive 
clones in the mature naive fraction of CD40L-defi  cient patients is higher 
than in controls. The proportions of HEp-2–reactive B cells in new emi-
grant (left) and mature naive (right) B cells from fi  ve controls and three 
CD40L-defi  cient patients, and (C) their evolution between these two 
B cell compartments are represented. Each diamond represents an 
individual, and the mean is shown with a bar. The controls shown include 
the two newly studied HD controls, HD08 and HD09, added to the previ-
ously reported controls (19, 21, 22). Statistically signifi  cant differences 
are indicated.JEM VOL. 204, July 9, 2007  1587
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a high frequency of ANA-reactive clones that represented, 
on average, 14.5% of this compartment and was signifi  cantly 
increased compared with healthy controls (P = 0.032; Fig. 3, 
B and C). In addition, all CD40L-defi  cient patients showed a 
higher proportion of ANA-expressing B cells in their mature 
naive B cell compartment than in the new emigrant B cell coun-
terpart from which they originated (Fig. 3 C). ANA-expressing 
B cells were found to display the highest amount of positively 
charged residues in their heavy chain CDR3s compared with 
nonreactive or autoreactive non-ANA clones (Fig. S1 and 
  Tables S1–S6). Autoreactive antibodies expressed by CD40L-
defi  cient mature naive B cells showed diverse antinuclear 
staining patterns (Fig. 3 D). Some autoantibodies (1–92, 1–195, 
and 2–45) presented a homogeneous nuclear staining, whereas 
other recombinant antibodies (3–57 and 3–146) gave a speck-
led nuclear staining pattern that may correspond to antibodies 
directed against nuclear proteins (23). Most ANA clones in 
CD40L-defi  cient patients presented a nucleolar staining pattern 
that was associated (1–172, 1–184, 1–188, 2–86, 3–28, and 
3–140) or not associated (1–17, 1–167, and 1–169) with the 
cytoplasmic reactivity that is often characteristic of anti-RNA 
polymerase complex antibodies (Fig. 3 D) (23). However, 
none of these autoantibodies recognized the condensed chro-
matin material in mitotic cells, suggesting that anti-DNA and 
chromatin-reactive clones are not recruited in the mature 
naive B cell pool of CD40L-defi  cient patients (unpublished 
data). To confi  rm this observation, we tested the antibody 
reactivity by indirect immunofl  uorescence on Crithidia luciliae. 
The kinetoplast of C. luciliae is an organelle composed of 
double-stranded (ds) DNA, and antibody recognition of the 
kinetoplast is the most specifi  c assay to identify antinative 
dsDNA routinely used for the detection of these autoantibodies 
in patients with systemic lupus erythematosus (SLE). We found 
that there were no B cells that recognize the kinetoplast of 
C. luciliae in either new emigrant or mature naive B cells from 
CD40L-defi  cient patients (unpublished data). We conclude that 
ANA B cells are properly counterselected in the bone marrow 
of CD40L-defi  cient patients. However, some ANA B cells 
accumulate in the mature naive B cell compartment in the 
absence of functional CD40L, which is most likely expressed 
by CD4+ T cells (24).
Peripheral B cell tolerance checkpoint requires MHC 
class II expression
The requirement of CD40L expression to counterselect 
human autoreactive B cells was reminiscent of a transgenic 
mouse model that demonstrated a role for CD4+ T cells in 
this process (17, 18). To characterize a potential role for cog-
nate B–T cell interactions, we analyzed B cell tolerance 
checkpoints in a BLS patient. BLS patients suff  er from a rare 
primary immunodefi  ciency disorder characterized by defec-
tive expression of MHC class II molecules (25, 26). A BLS 
patient provided a unique opportunity to analyze the role of 
MHC class II molecules in the establishment of B cell toler-
ance. Peripheral blood B cells from the BLS patient almost 
completely lacked an IgM−CD27+ class-switched memory 
B cell population, whereas the frequency of IgM+CD27+ un-
switched memory B cells was less aff  ected, demonstrating 
the essential role of MHC class II molecules in the develop-
ment of class-switched memory B cells in humans (Fig. 4 A). 
Similar to a majority of CD40L-defi  cient patients, the BLS 
patient also displayed an enlarged CD10+CD27− new emi-
grant B cell population compared with the age-matched HD 
control (Fig. 4 A and Fig. S2, available at http://www.jem
.org/cgi/content/full/jem.20062287/DC1). Indeed, the 
expansion of immature transitional/new emigrant B cells is 
frequently associated with human immunodefi  ciencies (27). We 
also confi  rmed that BLS B cells failed to express HLA-DR 
MHC class II molecules, whereas HLA-A,B,C MHC class I 
molecule expression was unaff  ected (Fig. 4 A). To determine 
Figure 3.  Mature naive B cells from CD40L-defi  cient patients 
express ANAs. (A) The frequency of self-reactive antibodies with nuclear 
(black bars) and cytoplasmic (gray bars) HEp-2 staining patterns, and the 
proportion of nonreactive antibodies (open bars) in new emigrant (right) 
and mature naive (left) B cells are shown for three controls and three 
CD40L-defi  cient patients. The data from three healthy controls (JH, HD08, 
and HD09) were pooled. (B) The frequency of ANA clones in the mature 
naive B cell compartment of CD40L-defi  cient patients is signifi  cantly 
higher than in healthy controls. The proportions of ANA-expressing B cells 
in new emigrant (left) and mature naive (right) B cells from controls and 
three CD40L-defi  cient patients and (C) their evolution between these two 
B cell compartments are represented. Each diamond represents an indi-
vidual, and the mean is shown with a bar. The controls shown include the 
two newly studied HD controls, HD08 and HD09, added to the previously 
reported control (21). Statistically signifi  cant differences are indicated. 
(D) Antibodies from CD40L-defi  cient mature naive B cells show diverse 
antinuclear staining including homogeneous (1–92, 1–195, 2–45), speckled 
(3–57 and 3–146), nucleolar and cytoplasmic (1–172, 1–184, 1–188, 2–86, 
3–28, and 3–140), and nucleolar only (1–17, 1–167, and 1–169).1588  DEFECT OF PERIPHERAL B CELL TOLERANCE IN CD40L DEFICIENCY | Hervé et al.
the impact of MHC class II expression on the establishment 
of human B cell tolerance, we tested the reactivity of 25 and 
29 antibodies cloned from single new emigrant B cells and 
mature naive B cells from the BLS patient, respectively. Because 
the BLS patient was a 3-yr-old child, we compared the reac-
tivity of his antibodies to that of antibodies obtained from 
single B cells from a young, HD control (HD09; Fig. 4). The 
reactivity of antibodies expressed by MHC class II-defi  cient 
new emigrant B cells was similar to that of the young control 
in both polyreactivity and HEp-2 reactivity ELISA assays 
(Fig. 4, B and C). Thus, MHC class II expression does not 
appear to be required for the removal of developing autoreac-
tive B cells during the central B cell tolerance checkpoint in 
the bone marrow. Similar to healthy adult donors, the fre-
quency of HEp-2–reactive clones dropped from 30% in new 
emigrant B cells to 19.3% in the mature naive B cell compart-
ment of the young HD09 control (Fig. 4 C). In contrast, the 
proportion of HEp-2–reactive mature naive B cells remained 
high (44.8%) in the BLS patient, and was similar to that of new 
emigrant B cells in this patient (Fig. 4 C). Contrary to CD40L-
defi  cient patients who also showed defects in the peripheral 
B cell tolerance checkpoint, the frequency of polyreactive 
Figure 4.  Mature naive B cells from a BLS patient express 
autoreactive antibodies. (A) A BLS patient showed decreased CD27+ 
memory B cells. Dot plots show CD27/IgM (top), CD10/CD27 (middle), 
and HLA-A,B,C/HLA-DR (bottom) expression on CD19+-gated B cells from 
a HD control HD09 (right) and a BLS patient. The BLS patient displayed 
decreased IgM–CD27+ class-switched and IgM+CD27+ memory B cell 
populations and an increased CD10+CD27– new emigrant B cell popula-
tion compared with HD controls. BLS B cells fail to express HLA-DR 
MHC class II molecules. (B) BLS B cells express polyreactive antibodies at 
a frequency similar to an age-matched control. Antibodies from new 
emigrant (left) and mature naive (right) B cells from a HD, HD09, and a 
BLS patient were tested in ELISA for reactivity with ssDNA, dsDNA, insulin, 
and LPS. Dashed lines show ED38-positive control (19, 54). Horizontal 
lines show cut-off OD405 for positive reactivity. For each individual, the 
frequency of polyreactive (fi  lled area) and nonpolyreactive (open area) 
clones is summarized in pie charts, with the number of antibodies tested 
indicated in the centers. (C) BLS mature naive B cells express HEp-2–
reactive antibodies. Antibodies from new emigrant (left) and mature naive 
(right) B cells from HD09 and a BLS patient were tested in ELISA for 
anti–HEp-2 cell reactivity. Dashed lines show ED38-positive control 
(19, 54). Horizontal lines show cut-off OD405 for positive reactivity. For 
each individual, the frequency of HEp-2–reactive (fi  lled area) and non–
HEp-2-reactive (open area) clones is summarized in pie charts, with the 
number of antibodies tested indicated in the centers.JEM VOL. 204, July 9, 2007  1589
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and ANA-expressing B cells remained low in the mature 
naive B cell compartment of the BLS patient (Fig. 4 B and 
Tables S7 and S8). We conclude that MHC class II expres-
sion is dispensable for central B cell tolerance, whereas it is 
important for the additional removal of autoreactive B cells in 
the periphery at the transition between new emigrant and 
mature naive B cells.
Decreased frequency of regulatory T cells 
in CD40L-defi  cient patients
CD40L expressed by CD4+ T cells and MHC class II 
require  ment for peripheral B cell tolerance suggested that this 
checkpoint may depend on cognate B–T interactions. Two pop-
ulations of T cells have been reported to express autoreactive 
TCRs that may be able to recognize self-antigens presented 
by autoreactive B cells: NKT cells that express TCRVα24 
combined to TCRVβ11 and CD4+CD25+CD127lo/– reg-
ulatory T (T reg) cells that express the transcription factor 
Foxp3 (28–31). Additional HD controls and CD40L-defi  cient 
patients were enrolled to study NKT and T reg cell frequen-
cies. The frequencies of NKT cells in CD40L-defi  cient and 
BLS patients were decreased compared with that of HDs, 
but diff  erences failed to reach statistical signifi  cance (Fig. 
S3, available at http://www.jem.org/cgi/content/full/jem
.20062287/DC1). In contrast, the frequency of T reg cells 
identifi  ed by the expression of CD25 either in the absence of 
or with low levels of IL-7 receptor/CD127 or in conjunc-
tion with Foxp3 was signifi  cantly decreased in all CD40L-
defi  cient patients compared with HDs (7.3% in controls vs. 
1.68% in CD40L-defi  cient patients; P < 0.00001; Fig. 5 A). 
The identifi  cation of T reg cells by intracellular detection of 
Foxp3 also revealed a signifi  cant decrease in the proportion 
of CD25+Foxp3+ T reg cells in CD40L-defi  cient patients in 
which these cells represent only 2.15% of their CD4+ T cells 
compared with 6.52% in controls (P < 0.00001; Fig. 5 B). In 
contrast, the proportion of T reg cells in the BLS patients was 
similar to HDs (Fig. 5). However, CD4+ T cells do not de-
velop normally in the absence of proper class II transactivator/
MHC class II molecule expression in BLS patients, and CD4+ 
T cell numbers were decreased by four- to fi  vefold compared 
with HDs (unpublished data) (32). Thus, similar to CD40L-
defi  cient patients, the absolute number of T reg cells in the 
BLS patient is also decreased by a factor of four to fi  ve. We 
conclude that T reg cells fail to develop or maintain in the 
absence of CD40L expression, and that decreased T reg cell 
numbers correlate with an altered peripheral B cell tolerance 
checkpoint in both CD40L-defi  cient and BLS patients.
Increased serum B cell-activating factor (BAFF) 
concentration in CD40L-defi  cient and BLS patients
BAFF is a critical B cell survival factor that controls the num-
ber of peripheral B cells (33). Transgenic mice overexpress-
ing BAFF develop a SLE–like disease by rescuing developing 
autoreactive B cells from deletion and allowing their accu-
mulation in the periphery (34–36). To determine whether 
the increased frequency of autoreactive B cells in the mature 
naive B cell compartment of CD40L-defi  cient and BLS pa-
tients results from increased BAFF levels, we measured by 
ELISA BAFF concentrations in the serum of these patients 
and compared them to that of HDs (Fig. 6). Serum BAFF 
levels in HDs were comparable among individuals, with an 
average concentration of 1,164 pg/ml. In contrast, serum 
BAFF levels were signifi  cantly increased by three- to fourfold 
in CD40L-defi  cient and BLS patients, in which it averaged 
3,259 and 4,514 pg/ml, respectively (CD40L-defi  cient, P < 
0.00001; Fig. 6). Thus, increased BAFF levels in CD40L-
defi  cient and BLS patients correlate with a defective peripheral 
B cell tolerance checkpoint in these patients.
D  I  S  C  U  S  S  I  O  N 
B cell tolerance is established by silencing developing auto-
reactive B cells. Two major checkpoints are responsible for 
the removal of these clones. A central B cell tolerance check-
point occurs in the bone marrow and counterselects most B cells 
ex  pressing highly polyreactive and ANA-expressing B cells (19). 
The peripheral B cell tolerance checkpoint removes additional 
Figure 5.  Low T reg cell frequency in CD40L-defi  cient patients. 
The frequency of T reg cells among peripheral CD4+ T cells was assessed 
by analyzing the proportion of CD25+CD127lo/– (A) and CD25+Foxp3+ 
(B) cells. Dot plots are shown for two healthy controls, three CD40L-
defi  cient patients, and the BLS patient (top), and the data collected for 
controls (open diamonds) and patients (fi  lled diamonds) are represented 
in the diagram. Each diamond represents an individual, and the mean is 
shown with a bar. The mean percentage of CD25+CD127lo/– cells among 
CD4+ T cells in HDs, 7.30 ± 1.6%; CD40L-defi  cient, 1.68 ± 0.5%; BLS, 
6.4%; mean percentage of CD25+Foxp3+ cells among CD4+ T cells in HDs, 
6.52 ± 0.9%; CD40L-defi  cient, 2.15 ± 0.6%; BLS, 5.8%. Statistically 
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autoreactive clones that may recognize self-antigens that were 
not expressed in the bone marrow environment. Little is known 
about the molecules and cell types involved in the regulation 
of these two checkpoints. We report that CD40L expression 
by T cells and MHC class II molecules are required for a 
functional peripheral B cell tolerance checkpoint in humans.
The frequency of autoreactive and polyreactive new emi-
grant B cells in CD40L-defi  cient and BLS patients was 
similar to that of HD controls, and therefore reveals that 
the central B cell tolerance checkpoint is functional in the 
absence of CD40L and MHC class II expression. Therefore, 
T cells expressing CD40L (24) and antigen presentation 
through MHC class II expression do not appear to play a role 
in counterselecting developing autoreactive immature B cells 
in the bone marrow. The regulation of central B cell tol-
erance seem to mainly involve sensing autoantigens binding 
to self-reactive BCRs on immature B cells (37, 38). Indeed, 
BCR triggering at this stage induces tolerance mechanisms, 
such as receptor editing, anergy, and, ultimately, deletion 
(20, 39). In humans, we previously reported that XLA patients, 
who carry mutations in the BTK gene, which encodes a 
cyto  plasmic tyrosine kinase that plays an essential role in 
mediating BCR signaling, display a high proportion of auto-
reactive new emigrant B cells (21, 40, 41). The alteration of 
BCR signaling thresholds results in defective central B cell 
tolerance checkpoint and in the release of developing auto-
reactive B cells in the periphery.
The high proportion of autoreactive mature naive B cells 
in both CD40L-defi  cient and BLS patients revealed defects of 
the peripheral B cell tolerance checkpoints in the absence of 
either CD40L or MHC class II expression. Defects of the 
peripheral B cell tolerance checkpoint were also identifi  ed 
by the abnormal enrichment in CD40L-defi  cient patients of 
mature naive B cells that expressed antibodies with highly posi-
tively charged IgH CDR3s. These CDR3s were reminiscent 
of those expressed by bone marrow early immature B cells 
that frequently expressed ANAs, and they are often coun-
terselected during early B cell development (19). Indeed, a 
majority of CD40L-defi  cient mature naive B cells were HEp-
2–reactive and/or polyreactive, including ANAs, which were 
found to display the highest amount of positively charged res-
idues in their CDR3s. The natural antibody repertoire of 
CD40L-defi  cient patients is biased toward specifi  c autoanti-
gens, and further demonstrates abnormal B cell tolerance 
mechanisms in the absence of CD40L expression (16). Thus, 
functional CD40L expression may maintain peripheral B cell 
tolerance by preventing the recruitment in the mature naive 
B cell compartment of autoreactive B cells, which may include 
ANA-expressing clones.
How may the absence of MHC class II or CD40L result 
in a failure to counterselect autoreactive clones in the mature 
naive B cell compartment? Although T–B cell interactions are 
severely compromised in the absence of either CD40L or 
MHC class II molecules and result in a failure to mount proper 
adaptive immune responses, it has been previously proposed 
that T–B cell interactions may also play an important role in 
the counterselection of autoreactive B cells in the periphery 
(17, 18). Using transgenic mouse models, CD4+ T cells and 
the receptor/ligand pairs CD40L–CD40 and Fas–FasL have 
been shown to play an important role in removing tolerant 
hen egg lysozyme-binding B cells (17, 18). In this model, self-
reactive B cells would present antigens via MHC class II mol-
ecules to CD4+ T cells and trigger CD40L expression. In 
return, CD40L would cross-link CD40 on these autoreactive 
B cells and induce the expression of the death receptor Fas 
that would trigger B cell apoptosis (18). Hence, defects in Fas 
or FasL lead to the production of autoantibodies that resem-
bled those found in SLE patients, both in mice and in humans 
(42–44). Our results agree with this model, and they further 
demonstrate an important role for T cells in counterselecting 
autoreactive B cells in humans.
What T cell subpopulation may be required for the estab-
lishment of peripheral B cell tolerance? Self-antigens captured 
by autoreactive BCRs may be presented to T cells through 
MHC class II molecules expressed on these autoreactive B cells. 
The putative T cells that may interact specifi  cally with these 
autoreactive B cells should therefore express autoreactive TCRs. 
Two populations of T cells have been reported to express 
autoreactive TCRs: NKT cells and CD4+CD25+ T reg cells 
(for review see [29]). Because the peripheral B cell tolerance 
checkpoint required MHC class II expression, NKT cells are 
not likely to be involved in peripheral B cell tolerance because 
these cells that express a very restricted TCRVα24/TCRVβ11 
repertoire recognize antigens presented by CD1 molecules 
(28). Indeed, we did not fi  nd any signifi  cant diff  erences in the 
frequency of NKT cells between HDs and CD40L-defi  cient 
and BLS patients. In contrast, T reg cells display a diverse 
TCR repertoire restricted to MHC class II molecules, express 
CD40L and can inhibit B cell proliferation (24, 29). T reg 
cells can also suppress B cell responses and induce B cell death 
in vitro (45, 46). It has been reported that T reg cells do not 
develop normally in mice in the absence of CD40L–CD40 
interactions (47, 48). In agreement with these observations, 
we found that CD40L-defi  cient patients displayed decreased 
Figure 6.  Elevated serum BAFF levels in CD40L-defi  cient and BLS 
patients. BAFF concentrations (pg/ml) in the serum of HD controls (open 
diamonds), six CD40L-defi  cient patients, and the BLS patient (fi  lled 
diamonds) were measured by ELISA. Each diamond represents an indi-
vidual, and the mean is shown with a bar: HD controls, 1,164 ± 364 pg/ml; 
CD40L-defi  cient, 3,259 ± 1,155 pg/ml; BLS, 4,514 pg/ml. Statistically 
signifi  cant differences are indicated.JEM VOL. 204, July 9, 2007  1591
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T reg cell numbers, suggesting that CD40L–CD40 interac-
tions may also play an important role in the development or 
maintenance of these T cells in humans. Lack of T reg cells 
leads to severe autoimmune disorders in Foxp3-defi  cient mice 
and humans, revealing that T reg cells are required for the 
establishment and/or the maintenance of peripheral tolerance 
(49–51). Both CD40L-defi  cient and BLS patients displayed 
low numbers of T reg cells and showed defects in peripheral 
B cell tolerance, suggesting that T reg cells may play an im-
portant role in preventing the accumulation of new emigrant/
transitional autoreactive B cells in the mature naive compart-
ment of these patients.
BAFF is a serum cytokine that promotes transitional and 
mature naive B cell survival. BAFF-defi  cient mice display 
profoundly decreased numbers of peripheral B cells (33). In 
contrast, mice overexpressing BAFF develop autoimmune 
disorders similar to SLE and Sjogren syndrome, which are 
characterized by the production of autoreactive antibodies, in-
cluding rheumatoid factor, anti-DNA, and other ANAs (34). 
Elevated BAFF concentration inhibits the counterselection of 
autoreactive new emigrant/transitional B cells that failed to be 
removed from the B cell population (35, 36). BAFF may also 
favor the proliferation of some clones by promoting the entry 
into the cell cycle (52). Hence, the elevated serum BAFF con-
centration in CD40L-defi  cient and BLS patients is likely 
to contribute to the accumulation of autoreactive mature naive 
B cells in the blood of these patients. Moreover, the increased 
frequency of B cells expressing ANAs in the mature naive 
compared with the new emigrant/transitional compartment of 
CD40L-defi  cient patients further suggest that elevated BAFF 
levels interfere with selection processes and result in the re-
cruitment of autoreactive mature B cells in these patients.
In conclusion, our results suggest that decreased T reg cell 
numbers, in combination with elevated serum BAFF levels, 
may be responsible for the accumulation of autoreactive ma-
ture naive B cells in the blood of CD40L-defi  cient and BLS 
patients. Thus, proper T reg cell number and function and 
balanced serum BAFF concentration are two key players reg-
ulating the peripheral B cell tolerance checkpoint by CD40L-
dependent mechanisms and through cognate B–T interactions.
MATERIALS AND METHODS
Patients. CD40L-defi  cient patients 1 and 4 are 8- and 2-yr-old brothers, 
respectively, who suff  er from a single nucleotide deletion at position 580 
(del580G), resulting in a frameshift and premature termination. CD40L-
  defi  cient patients 2 and 3 are 22- and 29-yr-old brothers, respectively, with 
a point mutation (G to C) in the splicing sequence of intron 4, which results 
in the deletion of exon 4 and in the absence of functional CD40L. CD40L-
defi  cient patient 5 is an 11-yr-old boy with a point mutation in exon 5, 
resulting in a single amino acid substitution (L195P). The CD40L-defi  cient 
patient 6 is a 34-yr-old male patient who has two point mutations in exon 4 
that result in the substitution of two adjacent amino acids (S128R and 
E129G) and prevent binding to CD40 (53). CD40L-defi  cient patient 7 is a 
9-yr-old boy with a nonsense mutation (Y26X) in exon 1 that has been pre-
viously described (5). The BLS patient is a 3-yr-old boy who displays a 
defective class II transactivator gene, which is responsible for the defect of 
MHC class II molecular expression (complementation analysis done by 
J. Villard, University of Geneva Medical School, Geneva, Switzerland). At the 
age of 4 mo, he developed a Pneumocystis carinii pneumonia, which required 
mechanical ventilation, and he remained at the hospital for several weeks. 
At that time, an immunological evaluation revealed hypogammaglobulinemia 
with an IgG of 24 mg/dl, IgA of below 6, IgM of 19, and severe T cell defi  -
ciency with a reverse CD4 to CD8 ratio. The young controls (HD08 and 
HD09) were recruited during a visit to the General Pediatric Endocrine 
Clinic at Weill Cornell Medical Center. HD08 is an overweight 14-yr-old 
Hispanic girl who was referred to the Pediatric Endocrine Clinic at age 13 
for the management of her weight and associated insulin resistance. She did 
not have any considerable past medical history. Her family history is negative 
for autoimmune-related disorders. Her physical examination was only re-
markable for the presence of acanthosis nigricans in the skin of the axillary 
area, which is a manifestation of insulin resistance. Control HD09 is a 5-yr-old 
Hispanic girl who presented to the General Endocrine Clinic at the age of  2 with 
headache and central precocious puberty. The donor is otherwise a healthy girl 
without any signifi  cant medical history; her family history is negative for auto-
immune disorders. Informed consent, as approved by the Institutional Review 
Board, was obtained from the parents or guardians of subjects <18 yr of age; 
in addition, consent was signed by children and adolescents >8 yr of age.
Single cell sorting and fl  ow cytometry.  Peripheral B cells were purifi  ed 
from the blood of CD40L-defi  cient and BLS patients and control donors by 
negative selection using the RosetteSep procedure (StemCell Technologies). 
Enriched B cells were stained with FITC anti–human CD27, PE anti–human 
CD10, anti–human IgM biotin, and allophycocyanin anti–human CD19 
(Becton Dickinson). Biotinylated antibodies were revealed using streptavidin-
PECy7 (Becton Dickinson). Single CD19+CD10+IgM+CD27− new emigrant 
and CD19+CD10−IgM+CD27− peripheral mature naive B cells from patients 
and control donors were sorted on a FACSVantage (Becton Dickinson) into 
96-well PCR plates containing 4 μl of lysis solution (0.5× PBS containing 
10 mM DTT, 8 U RNAsin [Promega], and 0.4 U 5′-3′ RNase Inhibitor 
[Eppendorf]) and immediately frozen on dry ice. All samples were stored at 
−70°C. For NKT and T reg cell analyses, peripheral mononuclear blood 
cells were stained either with FITC anti-TCRVα24, PE anti-TCRVβ11, 
(Immunotech), and PECy7 anti-CD3 or with FITC anti-TCRαβ, PE anti-
CD25, PECy7 anti-CD4, and allophycocyanin anti-CD127 (Becton Dickinson). 
Intracellular Foxp3 stainings were performed according to the manufacturer’s 
instructions (eBioscience).
cDNA, RT-PCR, antibody production, and purifi  cation. RNA  from 
single cells was reverse-transcribed in the original 96-well plate in 12.5-μl 
reactions containing 100 U of Superscript II RT (Invitrogen) for 45 min at 
37°C. RT-PCR reactions, primer sequences, cloning strategy, expression 
vectors, antibody expression, and purifi  cation were carried out as previously 
described (19, 54). Immunoglobulin sequences were analyzed by Ig Basic 
Local Alignment Search Tool comparison with GenBank. Heavy chain CDR3 
was defi  ned as the interval between the conserved cysteine at position 92 in the 
VH framework 3 and the conserved tryptophan at position 103 in JH segments.
ELISAs and IFAs. Antibody concentrations, reactivity against specifi  c 
antigens, and indirect immunofl  uorescence were determined as previously 
described (19, 54). Highly polyreactive ED38 was used as positive control in 
HEp-2 reactivity and polyreactivity ELISAs (19, 54). Antibodies were con-
sidered polyreactive when they recognized at least two, and usually all of the 
four, analyzed antigens that include single-stranded (ss) DNA, dsDNA, insulin, 
and LPS. For indirect immunofl  uorescence on C. luciliae, fi  xed C. luciliae–
coated slides (Antibodies, Inc.) were incubated at room temperature with 
purifi  ed recombinant antibodies at 50–150 μg/ml. FITC-conjugated goat 
anti–human IgG (Antibodies, Inc.) was used as a detection reagent. Serum 
BAFF concentration were determined by ELISA according to the manufacturer’s 
instruction (R&D Systems).
Statistics. Diff  erences between controls and patients were analyzed for sta-
tistical signifi  cance with unpaired Student’s t tests, using SigmaPlot software 
(Systat). A P value of < 0.05 was considered signifi  cant.1592  DEFECT OF PERIPHERAL B CELL TOLERANCE IN CD40L DEFICIENCY | Hervé et al.
Online supplemental material. Fig. S1 shows that mature naive B cells 
from CD40L-defi  cient patients are enriched in clones displaying highly posi-
tively charged heavy chain CDR3s. Fig. S2 shows that CD40L-defi  cient 
  patients often display a high proportion of new emigrant/transitional B cells. 
Fig. S3 shows NKT cell frequency in control, CD40L-defi  cient, and BLS 
patients. Antibody repertoires and reactivity from new emigrant and periph-
eral mature naive B cells from HDs, CD40L-defi  cient, and BLS patients 
are presented in Tables S1–S12. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20062287/DC1.
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